An Uncontrolled Open Label Multicenter Phase II Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma (HCC).
Phase of Trial: Phase II
Latest Information Update: 26 Aug 2014
At a glance
- Drugs Regorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Bayer
- 12 Mar 2013 Planned End Date changed from 1 Apr 2013 to 1 Mar 2013, as reported by ClinicalTrials.gov.
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Sep 2012 Planned end date changed from 1 Nov 2012 to 1 Apr 2013 as reported by ClinicalTrials.gov.